Pharmacological inhibition of DOT1L reduced hormone-responsive and endocrine-resistant BC cell proliferation rate and increased cell death both in vitro and in vivo, an effect due to the blockade of ERα signaling by epigenetic downregulation of ERα expression mediated by the HMT activity of this factor. This evidence concerns the gene ESR1 and breast cancer.